Newsroom

MD Anderson Research Highlights for December 18, 2024

December 18, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Smoking cessation medications are safe and effective for people with depression
Individuals with...

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research

BY Clayton Boldt

December 11, 2024

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center...

MD Anderson and AmMax Bio announce agreements to advance development of AMB-066 in colorectal cancer patients with minimal residual disease

BY Clayton Boldt

December 10, 2024

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical...

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

December 09, 2024

ABSTRACTS: 216, 219, 1011

SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual...